671816-46-9

Upstream product

• 671816-44-7 ethyl 4-(tert-butoxycarbonylhydrazono)cyclohexanecarboxylate 
• 870-46-2 t-butoxycarbonylhydrazine 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 

Downstream Products

• 916831-59-9 tert-butyl 1-(trans-4-ethoxycarbonylcyclohexane)-5-cyclopropyl-1H-pyrazole-4-carboxylate 
• 883864-66-2 (1r,4r)-ethyl 4-hydrazinylcyclohexanecarboxylate 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS

The present invention relates to heterocyclic compounds of formula 1, in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, carboxylic acid isosteres and N-oxides. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

METHOD FOR PRODUCING PYRROLIDINE COMPOUND

Provided is a method capable of efficiently producing a compound having a superior HSD1 inhibitory action and a compound useful as a synthetic intermediate therefor, with superior achievability of asymmetric synthesis (i.e., superior selectivity), superior yield, superior safety and superior industrial workability at a low cost. A method of producing a compound represented by the following formula [8]: or a salt thereof, or a solvate thereof, from a compound represented by the following formula [2]: or a reactive derivative thereof, or a salt thereof, or a solvate thereof.

Heterocyclic compounds

The present invention provides a compound represented by the following formula [1′] or a salt thereof: wherein ring A, R2, R3, R4 and X are as defined in the description, and an agent for the treatment or prophylaxis of a

1,4-SUBSTITUTED CYCLOHEXANE DERIVATIVES

Allylic compounds represented by the formula (I) are provided, wherein each of R1 to R8, m, n, A and X are as defined in the Specification. These compounds can inhibit Rho kinase, and can find utility in repair of damaged nerves in the central and peripheral nervous system by inducing axon growth and regeneration, and in the treatment by inhibition of Rho kinase in disease states in which Rho kinase is implicated. The compounds are relatively cell permeable and pharmaceutical compositions thereof can promote neurite growth and are also useful for the prevention of cell proliferation in malignant deseases.